Loxo Oncology Inc (NASDAQ:LOXO) CEO Joshua H. Bilenker Sells 15,000 Shares

Loxo Oncology Inc (NASDAQ:LOXO) CEO Joshua H. Bilenker sold 15,000 shares of Loxo Oncology stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $88.21, for a total value of $1,323,150.00. Following the transaction, the chief executive officer now directly owns 190,207 shares in the company, valued at approximately $16,778,159.47. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Loxo Oncology Inc (NASDAQ LOXO) traded up $1.71 during trading hours on Monday, hitting $93.94. The company had a trading volume of 153,252 shares, compared to its average volume of 317,969. Loxo Oncology Inc has a 12 month low of $40.01 and a 12 month high of $106.40. The company has a market cap of $2,810.00, a price-to-earnings ratio of -16.17 and a beta of 2.56.

Several large investors have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. raised its stake in shares of Loxo Oncology by 31.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,758 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 419 shares during the period. Wells Fargo & Company MN increased its stake in Loxo Oncology by 3.8% in the 2nd quarter. Wells Fargo & Company MN now owns 16,095 shares of the biopharmaceutical company’s stock worth $1,291,000 after acquiring an additional 592 shares during the last quarter. New York State Common Retirement Fund boosted its holdings in shares of Loxo Oncology by 2.9% in the 3rd quarter. New York State Common Retirement Fund now owns 25,097 shares of the biopharmaceutical company’s stock worth $2,312,000 after purchasing an additional 700 shares in the last quarter. California State Teachers Retirement System boosted its holdings in shares of Loxo Oncology by 3.1% in the 3rd quarter. California State Teachers Retirement System now owns 36,594 shares of the biopharmaceutical company’s stock worth $3,371,000 after purchasing an additional 1,094 shares in the last quarter. Finally, Legal & General Group Plc boosted its holdings in shares of Loxo Oncology by 36.2% in the 2nd quarter. Legal & General Group Plc now owns 5,014 shares of the biopharmaceutical company’s stock worth $405,000 after purchasing an additional 1,332 shares in the last quarter.

LOXO has been the topic of several research analyst reports. BidaskClub raised Loxo Oncology from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Zacks Investment Research raised Loxo Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. William Blair assumed coverage on Loxo Oncology in a research report on Tuesday, November 28th. They set an “outperform” rating on the stock. Ifs Securities raised Loxo Oncology from an “outperform” rating to a “strong-buy” rating in a research report on Tuesday, November 14th. Finally, JMP Securities raised Loxo Oncology from a “market perform” rating to an “outperform” rating and upped their price target for the company from $77.18 to $95.00 in a research report on Tuesday, November 14th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $97.33.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/12/loxo-oncology-inc-loxo-ceo-sells-1323150-00-in-stock.html.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply